Athersys Inc. (NASDAQ: ATHX)
Athersys Inc. (NASDAQ: ATHX) is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of its proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. The Company develops therapeutic products that "have best-in-class potential, meaning therapeutic candidates that have the potential to be safer and more effective products than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration." Their lead product development programs utilize MultiStem®, a patented and proprietary stem cell product that could be beneficial in the treatment for multiple disease indications in the cardiovascular, neurological, and inflammatory and immune disease areas, as well as certain other conditions. MultiStem is currently being evaluated in several clinical stage programs, as well as a range of preclinical programs. In addition, Athersys is developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions, as well as certain neurological disorders.
See all Athersys (NASDAQ: ATHX) articles at Daily Dose Equities.